An observational study in Pregnancy Related, Pregnancy Complications and Pregnancy, High Risk, sponsored by Sumitomo Pharma Switzerland GmbH. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-01.
Sponsored by Sumitomo Pharma Switzerland GmbH (part of Sumitomo Pharma Co., Ltd.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Pregnancy Complications with a site in United States — 39 open to participants now, 47 under way, 1 of them phase 3. Pregnancy Complications · United States.
Among the 127 studies in Pregnancy Complications with a site in United States, this one is the 26th largest by planned enrollment of the 61 observational ones that give a count, is one of 17 that started in 2025, is one of 61 observational ones, reaches primary completion later than 21 of the 46 other live ones, and was the 84th registered.
411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.
Browse Pregnancy Complications studies →39 of the 127 studies in Pregnancy Complications with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
University of Florida · Sites in United States
Ages 15–49 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
Kenneth Moise MD · Sites in United States
Ages 18–45 · Women only
Michigan State University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 8 · Phase 4 6
First in 1995; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 530 is above the median of 400 across 198 observational studies indexed under Pregnancy Complications.
Median enrollment 96 across the 66 interventional studies, 477 across the 61 observational. Of the 69 that completed or were terminated, 19 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma Switzerland GmbH, one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma Switzerland GmbH is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Sumitomo Pharma Co., Ltd. has 2 studies filed under Pregnancy Complications — fewer than ten, so there is no comparison to draw.
20 of the studies in Pregnancy Complications with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT06529042Mount Sinai Hospital, CanadaSCRIPT: Sickle Cell Risk in Pregnancy Tool | 2026-12 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06790043Albany Medical CollegeImpact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 127 studies in Pregnancy Complications with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care from healthcare providers (HCPs). The study is designed to evaluate the association between relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) exposure during pregnancy and subsequent fetal and infant outcomes.
The study will identify pregnant women exposed to relugolix combination therapy during pregnancy from a United States (US) administrative claims database. The primary outcome measure is major congenital malformations (MCMs) among linked live births. Secondary outcome measures include spontaneous abortion (SAB), stillbirth, small size for gestational age (SGA), and preterm birth. Infants of pregnancies with linked live birth outcomes will be followed up to 12 months of age for identification of MCMs. Anticipated enrollment is 530 live births.
The study population will include 2 cohorts: The exposed cohort will include pregnant women with conditions for which relugolix combination therapy is prescribed and who are exposed to relugolix combination therapy at any time during pregnancy. The unexposed cohort will include pregnant women with conditions for which relugolix combination therapy could be prescribed and who are not exposed to relugolix combination therapy at any time during pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort 1
Cohort 2
Exclusion Criteria:
Pregnant women with conditions for which relugolix combination therapy is prescribed, who are exposed to relugolix combination therapy at any time during pregnancy
Drug: Relugolix + Estradiol + Norethindrone Acetate
Pregnant women with conditions for which relugolix combination therapy could be prescribed, who are not exposed to relugolix combination therapy at any time during pregnancy
Drug pages: Relugolix · Estradiol · Norethindrone Acetate
Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
Also known as: MVT-601, MVT-601A, MYFEMBREE
Major Congenital Malformation (MCM)
Comparison of rate of MCM between cohorts
Time frame: Up to 5 years
Spontaneous abortion (SAB)
Comparison of rate of SABs between cohorts
Time frame: Up to 5 years
Stillbirth
Comparison of rate of stillbirths between cohorts
Time frame: Up to 5 years
Preterm birth
Comparison of rate of preterm births between cohorts
Time frame: Up to 5 years
Small for gestational age (SGA)
Comparison of rate of SGA between cohorts
Time frame: Up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sumitomo Pharma Switzerland GmbH →